Averion Revenues Double Following Hesperion Acquisition

Tuesday, November 18, 2008 12:22 PM

Averion, a contract research organization (CRO) specializing in oncology, reported its third quarter revenues more than doubled following its acquisition of Swiss CRO Hesperion.

Net service revenue for the three months ended September 30 was $15.9 million, compared with $7.8 million for the same period last year. The Southborough, Mass.-based company’s direct expenses for the third quarter of 2008 increased $5.7 million over third quarter 2007 to $9.9 million. The Hesperion acquisition, completed in October 2007, contributed $5.4 million to those third quarter expenses.

“We continued to realize positive trends in our net service revenue despite the difficulties facing many of our clients who are currently seeking additional sources of funds,” said Averion CEO Markus Weissbach, M.D., Ph.D., in a company statement. “We continue to manage our business very carefully and capitalize on the efficiencies of our expanded international operations through the integration of Hesperion and Averion.”

Averion expanded its European operations last month with the opening of a Czech Republic office, and the CRO continues to look for other expansion opportunities (both geographically and in the services it provides), according to Weissbach. Averion has U.S. offices in California, Maryland and New York; and international offices in France, the Netherlands, the United Kingdom, Poland, Russia, Israel, Germany, Austria, Ukraine and the Czech Republic.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs